In the news | 28th March 2022
Life science companies need to harness the predictive value of data to drive deeper process understanding. Here's how.
As the biopharmaceutical industry begins to embrace advanced data collection and analysis tools, it finds itself facing a challenging question: How can drug manufacturers best harness all that data to improve capacity, reduce bottlenecks and cut costs? Establishing a strong digital backbone is the first critical step. Learn more from Claire Hill, IDBS’ BPLM market engagement lead, in this article published in BioIT World.
Putting Your CMC Ontology to Work | Pistoia Alliance 2026
Join IDBS at the Pistoia Alliance conference as Ken Forman explores how organizations can transform a documented CMC ontology into a GxP-qualified operational framework. Learn how linking ontology to experimental data enables structured, submission-ready information, improving data exchange, regulatory compliance, and the efficiency of CMC processes.
CMC regulatory submissions: Why knowledge continuity matters
Biopharma organizations have invested heavily in managing CMC data, yet many continue to face a less visible challenge: preserving the knowledge behind critical development decisions. As products progress through development and teams evolve, maintaining scientific context can become just as important as maintaining the underlying data.
i3 2027 registration
IDBS i3 2027 brings together life sciences leaders to explore how connected data, AI, and modern informatics are transforming scientific innovation. Join us in Woking for 1.5 days of customer stories, expert insights, interactive sessions, and networking opportunities.
i3 Japan 2026
Join us at i3 Japan and be part of the conversation shaping the future of BioPharma in Japan. Hear real-world case studies from IDBS users and gain insights from IDBS experts on our solutions.
